Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07423065). This is a study registration, not published results. Lead sponsor: University of Primorska. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 34 participants (ESTIMATED). Conditions: Pre Diabetic, Obesity & Overweight. Interventions: DEVICE: Continuous Glucose Monitoring (CGM). Primary outcome measures: Change in Glycemic Variability Assessed by Coefficient of Variation from CGM , End of each 12-week CGM phase; Postprandial Glucose Excursions Measured by CGM , End of each 12-week CGM phase; Change in Mean Daily Energy Intake , End of each 12-week CGM phase. Brief summary: This randomized, crossover interventional study evaluates the effects of real-time (open) versus blinded continuous glucose monitoring (CGM) on glycemic variability, lifestyle behaviors, and metabolic outcomes in adults with prediabetes and overweight or obesity (BMI ≥ 27 kg/m²). Thirty participants will undergo both open and blinded CGM phases, separated by a washout period. The study aims to assess whether access to real-time glucose data promotes behavioral change and improves metabolic health compared with blinded CGM use.